Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Conditions: Accelerated Phase of Disease; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Myelomonocytic Leukemia; Chronic Phase of Disease; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Recurrent DiseaseInterventions: Drug: Tipifarnib; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Active, not recruiting - verified August 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials